Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 6.5% in that time frame, outperforming the S&P 500. But investors have to be ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Chegg's stock is down 99% as free AI tools like ChatGPT have made ...

Online homework helper Chegg said Monday that it will slash 45% of its workforce and bring back its previous CEO as it grapples with the “new realities of AI,” including reduced web traffic and ...

What just happened? AI's impact on jobs isn't always so direct as replacing workers. Chegg, the education tech company once valued at more than $12 billion, has said it is cutting 45% of its workforce ...

Chegg Inc., a Santa Clara-based online learning platform, said Monday it will cut about 45% of its workforce – roughly 388 employees – as it confronts what it calls "the new realities of AI and ...

If you were a lazy college student during Covid, imagine a time traveler from five years in the future telling you that something kind of like Chegg is coming soon—but this thing lets you be even ...